Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML

Blood (2017) 130 (4): 397–407.

https://doi.org/10.1182/blood-2017-01-763219

Published: 2017

Includes: Supplemental data

Journal Articles

PARP1 is required for chromosomal translocations

Justin Wray, Elizabeth A. Williamson, Sudha B. Singh, Yuehan Wu, Christopher R. Cogle, David M. Weinstock, Yu Zhang, Suk-Hee Lee, Daohong Zhou, Lijian Shao, Martin Hauer-Jensen, Rupak Pathak, Virginia Klimek, Jac A. Nickoloff, Robert Hromas

Blood (2013) 121 (21): 4359–4365.

https://doi.org/10.1182/blood-2012-10-460527

Published: 2013

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

Journal Articles

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, Virginia Klimek, MD, Jorge Cortes, MD, Farhad Ravandi, MD, Willie M. Newsome, RN, Julie Dumouchel, Marja Dubay, Zoumei Li, Christiane Maroun, Eric Laille, Hagop Kantarjian, MD, Robert E. Martell, MD, Selina Luger, MD

Blood (2007) 110 (11): 444.

https://doi.org/10.1182/blood.V110.11.444.444

Published: 2007

Journal Articles

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

David H. Chang, Nancy Liu, Virginia Klimek, Hani Hassoun, Amitabha Mazumder, Stephen D. Nimer, Sundar Jagannath, Madhav V. Dhodapkar

Blood (2006) 108 (2): 618–621.

https://doi.org/10.1182/blood-2005-10-4184

Published: 2006

Includes: Supplemental data

Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD

Blood (2005) 106 (11): 1156.

https://doi.org/10.1182/blood.V106.11.1156.1156

Published: 2005

Journal Articles

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Richard M. Stone, Daniel J. DeAngelo, Virginia Klimek, Ilene Galinsky, Eli Estey, Stephen D. Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin

Blood (2005) 105 (1): 54–60.

https://doi.org/10.1182/blood-2004-03-0891

Published: 2005

Journal Articles

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, Thomas Fischer

Blood (2005) 105 (1): 335–340.

https://doi.org/10.1182/blood-2004-02-0660

Published: 2005

Journal Articles

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

Hussain Saba, Craig Rosenfeld, Jean-Pierre Issa, John DiPersio, Azra Raza, Virginia Klimek, James Slack, Carlos de Castro, Karl Mettinger, Hagop Kantarjian

Blood (2004) 104 (11): 67.

https://doi.org/10.1182/blood.V104.11.67.67

Published: 2004

NARROW

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML

PARP1 is required for chromosomal translocations

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only